Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?

[1]  V. Bini,et al.  Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience. , 2016, Brachytherapy.

[2]  T. Bosse,et al.  Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.

[3]  D. Matei,et al.  Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Den,et al.  Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer , 2014, Journal of contemporary brachytherapy.

[5]  J. W. Kim,et al.  1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial , 2014 .

[6]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[7]  A. Rademaker,et al.  Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy. , 2012, International journal of radiation oncology, biology, physics.

[8]  C. Houser,et al.  Is there any advantage to three-dimensional planning for vaginal cuff brachytherapy? , 2012, Brachytherapy.

[9]  H. Andersson,et al.  External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma: A Prospective, Randomized Study—Quality-of-Life Analysis , 2012, International Journal of Gynecologic Cancer.

[10]  J. Delaloye,et al.  Intravaginal Brachytherapy in FIGO Stage I Low-Risk Endometrial Cancer: A Controlled Randomized Study , 2009, International Journal of Gynecologic Cancer.

[11]  Hye-Chun Hur,et al.  Incidence and patient characteristics of vaginal cuff dehiscence after different modes of hysterectomies. , 2007, Journal of minimally invasive gynecology.

[12]  Elettra Pignotti,et al.  Transvaginal evisceration after hysterectomy: is vaginal cuff closure associated with a reduced risk? , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[13]  E. Venkatraman,et al.  Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. , 2005, International journal of radiation oncology, biology, physics.

[14]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[15]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  Brady J. McKee,et al.  Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. , 2002, International journal of radiation oncology, biology, physics.

[17]  T. Mate,et al.  Adjuvant High Dose Rate Vaginal Brachytherapy as Treatment of Stage I and II Endometrial Carcinoma , 2002, Obstetrics and gynecology.

[18]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[19]  J. Anderson,et al.  High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. , 2000, International journal of radiation oncology, biology, physics.

[20]  M. Chadha,et al.  Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. , 1999, Gynecologic oncology.

[21]  C. Hess,et al.  Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy. , 1998, Gynecologic oncology.

[22]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.

[23]  D. Gaffney,et al.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. , 2017, Brachytherapy.

[24]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[25]  L. Landrum,et al.  Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. , 2014, Gynecologic oncology.

[26]  J. Rownd,et al.  American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. , 2012, Brachytherapy.

[27]  R. Kurman,et al.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study , 1991 .